📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Lyka Labs Completes Merger with Lyka Exports; Authorized Capital Rises to ₹59 Crore
Lyka Labs Limited has successfully completed the amalgamation of Lyka Exports Limited into itself, effective from April 8, 2026. The merger follows the sanction from the NCLT Ahmedabad Bench and the subsequent filing with the Registrar of Companies. The appointed date for this scheme is retrospectively set to April 1, 2022. Consequently, the company's authorized share capital has been increased to ₹59 crore to accommodate the merger requirements.
Key Highlights
Scheme of Amalgamation with Lyka Exports Limited became effective on April 8, 2026
The retrospective appointed date for the merger is April 1, 2022
Authorized share capital increased to ₹59,00,00,000 (₹59 Crores)
New capital structure consists of 5.7 crore equity shares of ₹10 each and 2 lakh preference shares
Consolidation aims to streamline operations and integrate the export business directly
💼 Action for Investors
Investors should view this consolidation as a positive step toward corporate simplification and operational synergy. Monitor upcoming financial statements for the impact of the integrated export business on the bottom line.
Loading analysis...
NCLT Approves Merger of Lyka Exports Limited with Lyka Labs Limited
The National Company Law Tribunal (NCLT), Ahmedabad Bench, has officially approved the Scheme of Amalgamation between Lyka Exports Limited and Lyka Labs Limited. The order was granted on March 16, 2026, following a petition filed in 2024. Notably, the merger has a retrospective appointed date of April 1, 2022, which will lead to a consolidation of financial statements from that period. The company is now completing the final regulatory step of filing e-form INC-28 with the Registrar of Companies within the 30-day deadline.
Key Highlights
NCLT Ahmedabad Bench approved the merger on March 16, 2026
The appointed date for the amalgamation is retrospectively set as April 1, 2022
Lyka Exports Limited (Transferor) will be fully merged into Lyka Labs Limited (Transferee)
Company to file e-form INC-28 with the Registrar of Companies within 30 days to finalize the process
💼 Action for Investors
Investors should view this as a positive consolidation move that may improve operational efficiencies; however, they should review the upcoming consolidated financial statements to understand the impact of the 2022 retrospective appointed date.
Loading analysis...
Lyka Labs Amalgamation Update: NCLT Reserves Order Following FEMA Compliance Review
Lyka Labs Limited has provided a regulatory update regarding its ongoing Scheme of Amalgamation. The National Company Law Tribunal (NCLT) has reviewed the company's submissions and affidavits concerning FEMA compliance and Import Export Code guidelines. Following these submissions, the NCLT has officially reserved its order on the matter. This indicates that the judicial hearing phase is complete, and a final decision on the merger is expected shortly.
Key Highlights
NCLT has reserved the final order regarding the Scheme of Amalgamation for Lyka Labs.
Company submitted compliance affidavits related to FEMA guidelines and Import Export Code as directed.
The update follows a previous regulatory intimation dated February 2, 2026.
The tribunal's jurisdiction covers both the Transferor and Transferee companies involved in the deal.
💼 Action for Investors
Investors should await the final NCLT order as it will determine the legal completion of the merger. Monitor the stock for price sensitivity once the final judgment is made public.
Loading analysis...
Lyka Labs Amalgamation Update: NCLT Hearing Scheduled for February 19, 2026
Lyka Labs Limited has provided a procedural update regarding its ongoing Scheme of Amalgamation before the NCLT Ahmedabad Bench. During the hearing on January 29, 2026, the company confirmed it has complied with all previous tribunal orders. The NCLT is currently examining an affidavit filed by the company specifically regarding FEMA compliance. The matter has now been listed for a subsequent hearing on February 19, 2026.
Key Highlights
NCLT Ahmedabad Bench reviewed the amalgamation application on January 29, 2026
Company confirmed compliance with all previous orders passed by the Hon’ble Tribunal
Tribunal is currently examining a specific affidavit regarding FEMA compliance
Next hearing for the amalgamation scheme is scheduled for February 19, 2026
💼 Action for Investors
Investors should track the outcome of the February 19 hearing as the amalgamation is a significant corporate restructuring event. Maintain a watch on the stock for any volatility leading up to the final NCLT approval.
Loading analysis...
Lyka Labs Q3 Results: Standalone Profit Jumps to ₹2.7 Cr; Consolidated Swings to Loss
Lyka Labs reported a mixed performance for the quarter ended December 31, 2025. On a standalone basis, the company saw a significant jump in net profit to ₹269.85 lakhs from ₹26.14 lakhs in the previous year. However, the consolidated results show a net loss of ₹15.12 lakhs compared to a profit of ₹270.40 lakhs in Q3 FY25, driven by a 9% decline in consolidated revenue. The company also accounted for a one-time impact of ₹11.41 lakhs related to new Labour Code regulations.
Key Highlights
Standalone Net Profit surged to ₹269.85 lakhs from ₹26.14 lakhs YoY.
Consolidated Revenue from operations fell to ₹3,072.80 lakhs from ₹3,379.76 lakhs YoY.
Consolidated bottom line swung to a loss of ₹15.12 lakhs from a profit of ₹270.40 lakhs in the year-ago period.
Company paid a premium of ₹217.14 lakhs on the redemption of 1,08,570 preference shares, adjusted against General Reserve.
Recognized a one-time incremental impact of ₹11.41 lakhs under Employee Benefit Expenses due to new Labour Codes.
💼 Action for Investors
Investors should exercise caution as the consolidated performance indicates significant weakness in subsidiaries, leading to an overall group loss despite standalone growth. Monitor the company's ability to stabilize consolidated margins in the upcoming quarters.
Loading analysis...
Lyka Labs Amalgamation Order Delayed; NCLT Sets Next Hearing for January 29, 2026
Lyka Labs has provided an update regarding its Scheme of Amalgamation currently under review by the NCLT Ahmedabad Bench. While the order was previously reserved on December 5, 2025, the tribunal called for further clarifications on December 18, 2025. Consequently, the matter has now been scheduled for further consideration on January 29, 2026. This delay extends the timeline for the completion of the merger process for both the Transferor and Transferee companies.
Key Highlights
NCLT Ahmedabad Bench had previously reserved the order on December 5, 2025.
The matter was listed for further clarification on December 18, 2025.
The next hearing for further consideration is scheduled for January 29, 2026.
The amalgamation involves both the Transferor and Transferee companies under the same jurisdiction.
💼 Action for Investors
Investors should monitor the outcome of the January 29 hearing as it will determine the progress of the merger. The delay may cause short-term price volatility due to extended uncertainty.
Loading analysis...
LYKALABS: NCLT reserves order on Scheme of Amalgamation
Lyka Labs Limited announced that the Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, has reserved its order regarding the Scheme of Amalgamation. This follows an earlier update on November 8th, 2025, and a last opportunity granted to the Income Tax counsel to file a reply. The Income Tax Department's counsel has stated no objection to the merger application. The company received a copy of the NCLT order on December 5th, 2025.
Key Highlights
NCLT Ahmedabad Bench reserved its order on the Scheme of Amalgamation.
Income Tax Department's counsel has no objection to the merger application.
Company received NCLT order copy on December 5th, 2025.
💼 Action for Investors
Investors should monitor further announcements from the company regarding the NCLT order. Review the company's website for more information on the amalgamation scheme.